PT  - JOURNAL ARTICLE
AU  - Tunc, Huseyin
AU  - Sari, Fatma Zehra
AU  - Darendeli, Busra Nur
AU  - Nashebi, Ramin
AU  - Sari, Murat
AU  - Kotil, Seyfullah
TI  - Analytical solution of equivalent SEIR and agent-based model of COVID-19; showing the bounds of contact tracing
AID  - 10.1101/2020.10.20.20212522
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.20.20212522
4099  - http://medrxiv.org/content/early/2020/10/21/2020.10.20.20212522.short
4100  - http://medrxiv.org/content/early/2020/10/21/2020.10.20.20212522.full
AB  - Mathematical models not only forecast the possible future but also is used to find hidden parameters of the COVID-19 pandemic. Numerical estimates can inform us of both goals. Still, the interdependencies of parameters stay obscure. Many numerical solutions have been proposed so far; however, the analytical relationship between the outbreak growth, decay and equilibrium are much less studied. In this study, we have employed both an equivalent agent-based model and a Susceptible-Exposed-Infected-Recovered (SEIR)-like model to prove that the growth rate can be determined analytically in terms of other model parameters, including contact tracing rate. We identify the most sensitive parameters as undocumented transmission rate and documentation ratio. Unfortunately, these are the parameters we have the least knowledge. We derived an identity that predicts the effectiveness of contact tracing in a country from observable parameters. We underline an unavoidable dilemma: that even in the case of high contact tracing, we cannot bring the outbreak to stalemate without applying substantial quarantine; however, some countries are benefiting from contact tracing. Besides, we have shown that the seemingly same parameters of the SEIR models and agent-based models are not equivalent. We propose a correction to bridge both models.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funding was provided by TUBITAKAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCodes are available by request